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BACkgROuNd
The prevalence of arterial hypertension lacking a defined underlying 
cause increases with age. Age-related arterial hypertension is 
insufficiently understood, yet known characteristics suggest an 
aldosterone-independent activation of the mineralocorticoid 
receptor. Therefore, we hypothesized that 11β-HSD2 activity is  
age-dependently impaired, resulting in a compromised intracellular 
inactivation of cortisol (F) with F-mediated mineralocorticoid 
hypertension.
METhOdS
Steroid hormone metabolites in 24-h urine samples of 165 
consecutive hypertensive patients were analyzed for F and 
cortisone (e), and their TH-metabolites tetrahydro-F (THF), 5αTHF, 
TH-deoxycortisol (THS), and THe by gas chromatography-mass 
spectroscopy. Apparent 11β-HSD2 and 11β-hydroxylase activity and 
excretion of F metabolites were assessed.
RESulTS
In 72 female and 93 male patients aged 18–84 years, age  
correlated positively with the ratios of (THF + 5αTHF)/THe  
(P = 0.065) and F/e (P < 0.002) suggesting an age-dependent 
reduction in the apparent 11β-HSD2 activity, which persisted  
(F/e; P = 0.020) after excluding impaired renal function. excretion of  
F metabolites remained age-independent most likely as a 
consequence of an age-dependent diminished apparent  
11β-hydroxylase activity (P = 0.038).
CONCluSiON
Reduced 11β-HSD2 activity emerges as a previously unrecognized 
risk factor contributing to the rising prevalence of arterial 
hypertension in elderly. This opens new perspectives for targeted 
treatment of age-related hypertension.
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The prevalence of hypertension increases with age. Normo-
tensive individuals at the age of 55 years have a 90% chance 
of  becoming hypertensive over their remaining life span. 
At present, 80% of individuals aged ≥70 years in North 
America, Europe, Japan, and Australia have a blood pressure 
≥140/90 mm Hg or are  taking antihypertensive medication. 
The resulting cardiovascular disease is by far the leading cause 
of death and disability in persons aged >70 years in the United 
States and other  westernized countries.
Antihypertensive therapy is effective even in very old 
patients by reducing cardiovascular complications, yet reach-
ing blood pressure goals is more difficult in geriatric than in 
young patients. In most elderly patients, a nonspecific com-
bination of multiple antihypertensive drugs is used to control 
blood pressure. Reduced adherence and increased frequency 
of side effects are the consequences of such a combination 
therapy. Both factors introduce a risk for undertreatment in up 
to 55% of elderly individuals with hypertension. Consequently, 
a more specific treatment approach targeting the causative 
mechanism of hypertension is warranted.
The underlying causes of age-related hypertension have 
not been completely elucidated so far. Increased salt sen-
sitivity is a characteristic of hypertension in elderly.1 Salt 
sensitivity in younger persons has been attributed at least 
in part to a reduced activity of the 11β-hydroxysteroid 
 dehydrogenase type 2 enzyme (11β-HSD2).2–5 The NAD-
dependent 11β-HSD2 determines intracellular, but not sys-
temic,  cortisol availability for the mineralocorticoid receptor 
by  inactivating cortisol into cortisone.6,7 The 11β-HSD2 
enzyme is a  gatekeeper for the mineralocorticoid receptor 
preventing its inappropriate stimulation by the glucocorti-
coid  cortisol. Stimulation of the mineralocorticoid receptor 
by cortisol as observed in subjects with a loss-of-function 
mutation of the 11β-HSD2 or with a pharmacologically 
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inhibited 11β-HSD2 activity results in  volume expansion 
and arterial hypertension.6,8,9
Ageing contributes to changes in enzyme activity and avail-
ability by various mechanisms including methylation of genes, 
a mechanism known to affect 11β-HSD2 expression.10–12 
Thus, it is conceivable that hypertension in older age is asso-
ciated with an age-related reduction in  overall 11β-HSD2 
activity. To test the novel hypothesis of an age dependency of 
11β-HSD2 activity, we conducted a study in a sample of adult 
subjects with arterial hypertension throughout a broad age 
range.
METhOdS
Study population and study design. Patients were recruited 
from the Department of Nephrology and Hypertension, 
University Hospital Bern. Between 2002 and 2006, we screened 
465 consecutive outpatients. The patients were referred for 
arterial hypertension, kidney diseases, endocrinological dis-
orders, obesity, or osteopenia/osteoporosis and examined for 
urine steroid metabolite excretion. Inclusion criteria were a 
diagnosis of arterial hypertension as defined by a systolic and 
diastolic blood pressure ≥140 and ≥90 mm Hg, respectively, 
without or by antihypertensive therapy to control blood pres-
sure, and a complete data set comprising basic patient’s demo-
graphics, presence of associated diseases, laboratory results, 
blood pressure levels, and type of drugs taken at the time of 
steroid hormone metabolite analysis. The study was approved 
by the institutional review committee.
Patients were excluded if one or more of the following con-
ditions were present: pregnancy, thyroidal, parathyroidal or 
other overt endocrinological disorders apart from diabetes 
mellitus, secondary forms of arterial hypertension other than 
chronic kidney disease, cytolytic or cholestatic hepatopathy, 
urinary protein excretion >1 g/24 h, and/or documented intake 
of one or more of the following xenobiotics: liquorice, diuret-
ics, ACE inhibitors, angiotensin II receptor antagonists, antibi-
otics, β-blockers, drosperinone, or exogenous glucocorticoids. 
With these strict criteria, a study population of 165 patients 
was selected.
Serum and urine sampling. Creatinine, sodium, potassium, 
albumin, bilirubin, alkaline phosphatase, aspartate, and 
alanine aminotransferase were measured in serum  samples 
with standard laboratory methods. Creatinine clearance 
(CrCl) was calculated using the Cockcroft-Gault’s formula 
standardized for body surface area. A cutoff of <60 ml/
min/1.73 m2 for CrCl was used to define patients with mod-
erately or severely impaired renal function. Urine sampling 
was performed to measure urinary protein and steroid 
hormone metabolites corrected for the urinary creatinine 
 concentration. Antihypertensive medication was totally with-
drawn 1 week (spironolactone 2 weeks) before and during 
urinary steroid hormone analysis, if reasonable according to 
clinical judgment by the physician in charge of the patient, or 
 substituted by a calcium-channel blocker or an α-blocker or a 
 combination hereof.
Urinary steroid hormone analysis by gas chromatography-
mass spectroscopy. In 24-h urine samples, excreted corti-
sol (F), cortisone (E), tetrahydro-F (THF), 5αTHF, THE, 
and TH-deoxycortisol (THS) were measured with gas 
 chromatography-mass spectroscopy as described previously 
by Shackleton and reported by our group.13,14
The apparent 11β-HSD2 enzyme activity was obtained by 
calculating the urinary ratio of F/E and the corresponding 
ratio of their TH-metabolites (THF + 5αTHF)/THE (Table 1). 
As an index for the 11β-hydroxylase enzyme activity, the 
THS/(THF + 5αTHF) ratio was analyzed. High ratios of the 
urine metabolites indicate high substrate and low product 
concentrations and reflect low enzyme activity. Excretion of F 
metabolites was determined as Σ(F + E) and Σ(THE + THF + 
5αTHF) to obtain a measure for systemic F production and 
to exclude alterations of the availability of those substrates 
used to calculate changes in enzyme activity as a confounding 
variable. To correct for variations in urine collection, urinary 
excretion of steroid hormone metabolites was expressed as µg 
steroid hormone metabolite per mmol of urinary creatinine 
excretion.
Statistical analysis. Data were expressed as means ± s.d. unless 
otherwise stated. Age, CrCl, and systolic as well as diastolic 
blood pressure were successfully tested for standard normal 
distribution. First-order linear regression modeling and cor-
relations were chosen to analyze the relationship between age 
and 11β-HSD2 enzyme activity expressed as F/E and (THF + 
5αTHF)/THE ratios. The same approach was chosen to test for 
correlations between renal function and 11β-HSD2 enzyme 
activity as well as between age and apparent 11β-hydroxylase 
enzyme activity expressed as THS/(THF + 5αTHF) ratio. 
A multivariate linear regression model for the effect of age, 
renal function, and gender on F/E, (THF + 5αTHF)/THE, 
THS/(THF + 5αTHF) ratios and for F metabolite excretion 
expressed as the sums of (THF + 5αTHF + THE) and (F + E), 
Table 1 | Mean (±s.d.) urinary steroid hormone metabolite levels 
and derived ratios of metabolites
Steroid hormone
Steroid hormone metabolite 
measured x ± s.d.
11-Deoxycortisol THS (µg/day) 75.5 ± 44.4
Cortisol F (µg/day) 105 ± 61
THF (µg/day) 2232 ± 1083
5αTHF (µg/day) 2025 ± 1460
Cortisone e (µg/day) 134 ± 63
THe (µg/day) 5193 ± 2766
Derived indicators of steroid hormone metabolism
 F/e 0.82 ± 0.41
 (THF + 5αTHF)/THe 0.85 ± 0.28
 F + e (µg/mmol creatinine) 21.6 ± 9.64
 THe + THF + 5αTHF (µg/mmol creatinine) 793 ± 373
 THS/(THF + 5αTHF) 0.02 ± 0.01
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respectively, was applied. χ2 testing was used to identify differ-
ences on categorical and dichotomized data.
To deal with nonlinearity in the relationship between out-
come and continuous predictors, a systematic multivariable 
model building approach based on fractional polynomials was 
used.15 Power transformations are chosen from a restricted set 
S = {−2, −1, −0.5, 0, 0.5, 1, 2, 3}, where X0 denotes log(X). The 
set includes no transformation and the reciprocal, logarithmic, 
square root, and square transformations. To fit the model, each 
of the eight values was tried, the best-fitting model being the 
one with the highest likelihood. Regression lines in figures are 
based on best-fitting fractional polynomials and are the partial 
linear predictor for the variable in question (age or CrCl). All 
statistical analyses were performed using STATA version 9.2. 
Significance was assigned at P < 0.05.
RESulTS
demographics
A total of 165 patients (93 male, 72 female) with arterial hyper-
tension were included in the final analysis and presented with 
a predominant white background (n = 156 patients); nine 
patients were of Asian origin. Major comorbidities consisted of 
chronic kidney disease (n = 44), coronary heart disease/heart 
failure (n = 25), and diabetes mellitus (n = 10).
Age distribution ranged from 18 to 84 years (mean age 
49.6 years) with 36.7% of patients >60 years. The mean body 
mass index (BMI) was 27.1 ± 5 kg/m2 (range 17.6–49.9 kg/m2) 
and systolic, diastolic, and mean blood pressure were 155 ± 
20 mm Hg (range 112–210 mm Hg), 96 ± 12 mm Hg (range 
65–130 mm Hg) and 116 ± 12 mm Hg (range 87–157 mm Hg), 
respectively. The mean calculated CrCl was 91 ± 25.7 ml/
min/1.73 m2 (range 23–136 ml/min/1.73 m2). Moderately or 
severely impaired renal function was present in 25 of 165 patients 
including 18 who were >60 years. In total, 102 patients received 
an antihypertensive therapy at the time of analysis consisting of 
either a calcium channel and/or an α-blocker.
Analysis of apparent 11β-hSd enzyme activity
The mean steroid hormone metabolite levels are given in 
Table 1. The ratio of urinary (THF + 5αTHF)/THE tended 
to increase (P = 0.06) and the ratio of urinary F/E clearly 
rose with increasing age (P = 0.002) (Figure 1a,b), suggest-
ing a reduced apparent 11β-HSD2 activity in elderly per-
sons. The activity of 11β-HSD2 was inversely correlated with 
renal function ((THF + 5αTHF)/THE, P < 0.001; F/E: P < 
0.001) (Figure 2a,b). Best fit regression modeling applied as 
described in the Method’s section was identical with a linear 
regression model except in the comparison of F/E and CrCl, 
where the consideration of a polynomial model indicated a 
pronounced decrease in apparent 11β-HSD2 activity with 
reduced renal function only (Figure 2b). Even after exclu-
sion of patients with a CrCl <60 ml/min/1.73 m2, no relation 
between (THF + 5αTHF)/THE ratios and age was found (P = 
0.33) (Figure 3a); in contrast, the correlation of the F/E ratio 
with age remained after exclusion of patients with a CrCl 
<60 ml/min/1.73 m2 (P = 0.002, Figure 3b).
A multivariate linear regression model was applied to 
test the association between age, gender, or renal function 
and the (THF + 5αTHF)/THE and the F/E ratios, respec-
tively (Table 2). Elevated (THF + 5αTHF)/THE (P = 0.002) 
and F/E (P = 0.005) ratios indicating a diminished apparent 
11β-HSD2 activity were associated with reduced renal func-
tion. In addition, the (THF + 5αTHF)/THE ratio was higher 
in men than in women (P = 0.001). Taking into account the 
unselected total study population, the correlation between 
age and (THF + 5αTHF)/THE or F/E were not significant in 
the  multivariate models. After exclusion of individuals with 
a moderate to severely impaired renal function with a CrCl 
<60 ml/min/1.73m2, the F/E ratio was correlated with age (P = 
0.02) after adjusting for CrCl and gender (Table 2).
When the patients with a normal renal function (>70 ml/
min/1.73 m2) were dichotomized with respect to the 11β-HSD2 
activity, 96% of patients with an F/E ratio >0.9 ( indicating a 
reduced apparent 11β-HSD2 enzyme  activity), but only 74% of 
patients with a ratio <0.9, had a systolic hypertension defined 
as ≥140 mm Hg (χ2 12.7; P < 0.001), though both groups of 
patients had antihypertensive therapy with calcium channel 
and α-blockers prescribed as clinically required. No such  cutoff 
was identified for an elevated diastolic blood pressure.
Analyses of systemic cortisol production as assessed by  
urinary cortisol metabolite excretion
To elucidate whether differences in steroid hormone produc-
tion were explanatory for altered F/E or (THF + 5αTHF)/
THE ratios, the urinary excretion of cortisol metabolites used 
to calculate the apparent 11β-HSD2 activity was  quantified 
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Figure 1 | Linear correlation between age and urinary ratios of (a) (THF + 
5αTHF)/THe (r = 0.14, P = 0.06) or (b) F/e (r = 0.25, P = 0.002) (n = 165). 5αTHF, 
5α-tetrahydrocortisol; e, cortisone; F, cortisol; THe, tetrahydrocortisone;   
THF, tetrahydrocortisol; THS, tetrahydrodeoxycortisol.
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(Table 1). The cumulative amounts of urinary THF + 5αTHF + 
THE or F + E were independent of age, gender, or renal func-
tion (Table 3), which would best be explained by a reduced 
11β-hydroxylase activity.
Analyses of the apparent 11β-hydroxylase enzyme activity
The apparent 11β-HSD2 activity decreased with age as shown 
in Figure 3b. Similarly, the apparent 11β-hydroxylase activ-
ity as assessed by the urinary ratio of THS/(THF + 5αTHF) 
diminished with age (P = 0.005; Figure 4), even in multivariate 
analyses (P = 0.04) correcting for gender and CrCl (Table 4).
diSCuSSiON
Uncontrolled arterial hypertension is extremely common in 
elderly persons and results in extensive cardiovascular morbid-
ity and mortality. Here, we demonstrate for the first time that 
11β-HSD2 activity as assessed by the urinary ratio of F/E declines 
with age in a hypertensive population and therefore might con-
tribute to the development of hypertension in  elderly patients.
Both the F/E and the (THF + 5αTHF)/THE ratios are estab-
lished, though indirect markers, used to estimate the 11β-HSD 
activity. Several authors, but not all, suggested that the F/E 
ratio reflects the renal 11β-HSD2, and the (THF + 5αTHF)/
THE ratio the overall 11β-HSD activity, which comprises both 
the renal 11β-HSD2 and the hepatic 11β-HSD1 activity.9,16–22 
This assumption is supported by the recent demonstration 
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Figure 2 | Correlations between renal function (creatinine clearance = CrCl)  
and the urinary ratios of (a) (THF + 5αTHF)/THe (r = −0.26, P < 0.001) or  
(b) F/e (solid lines, linear: r = −0.32, P < 0.001; dotted lines, polynomial: P < 
0.001) (n = 165). The linear and polynomial correlations are depicted by 
straight and dashed lines, respectively. 5αTHF, 5α-tetrahydrocortisol;  
e, cortisone; F, cortisol; THe, tetrahydrocortisone; THF, tetrahydrocortisol;  
THS, tetrahydrodeoxycortisol.
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Figure 3 | Correlation between age and urinary ratios of (a) (THF + 5αTHF)/
THe (r = 0.08, P = 0.33) or (b) F/e (r = 0.26, P = 0.002) in patients with 
preserved renal function (creatinine clearance >60 ml/min) (n = 139). 5αTHF, 
5α-tetrahydrocortisol; e, cortisone; F, cortisol; THe, tetrahydrocortisone; THF, 
tetrahydrocortisol; THS, tetrahydrodeoxycortisol.
Table 2 | Multivariate linear regression analyses of the effect of age, gender, and creatinine clearance on apparent 11β-hSd activity
F/E (THF + 5αTHF)/THE
Regression coefficient ± s.e. 95 % CI P Regression coefficient ± s.e. 95 % CI P
Total study population (n = 165)
 Age 0.002 ± 0.002 −0.002 to 0.007 0.31 <0.001 ± 0.002 −0.003 to 0.036 0.74
 Female gender −0.014 ± 0.063 −0.138 to 0.110 0.83 −0.148 ± 0.04 −0.231 to −0.657 ≤0.001
 CrCl −0.004 ± 0.001 −0.007 to −0.001 0.005 −0.003 ± 0.001 −0.005 to −0.001 0.002
Subjects with CrCl >60 ml/min/1.73 m2 (n = 139)
 Age 0.005 ± 0.002 0.001 to 0.009 0.02 <0.001 ± 0.002 −0.003 to 0.004 0.78
 Female gender −0.006 ± 0.056 −0.115 to 0.104 0.92 −0.127 ± 0.047 −0.220 to −0.034 0.008
 CrCl 0.001 ± 0.002 −0.004 to 0.002 0.64 −0.003 ± 0.001 −0.005 to 0.001 0.06
Boldface indicates significant differences.
5αTHF, 5α-tetrahydrocortisol; CI, confidence interval; CrCl, creatinine clearance; E, cortisone; F, cortisol; THE, tetrahydrocortisone; THF, tetrahydrocortisol.
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of a stronger correlation between renal 11β-HSD2 mRNA 
 expression and urinary F/E than with urinary (THF + 5αTHF)/
THE ratios.23 Thus, our observation of an association between 
age and F/E rather than between age and (THF + 5αTHF)/THE 
ratio supports the conclusion that a reduced 11β-HSD2 contrib-
utes to the development of hypertension with increasing age. 
Obviously, the best proof of a link between 11β-HSD2 activity 
and blood pressure would be a direct association between F/E 
ratios and blood pressure. Such a relationship was obscured 
by the necessity to treat the majority of the patients and by the 
fact that the decision to discontinue antihypertensive drugs was 
also based on factors other than solely blood pressure values, 
such as the cardiovascular risk of the individual. In the mul-
tivariate analysis, antihypertensive medication was therefore 
not analyzed for its correlation with the apparent 11β-HSD2 
 activity. Nevertheless, in patients with an unaffected renal func-
tion, systolic blood pressure appears to be less well controlled 
in the presence of a reduced apparent 11β-HSD activity.
Age-related changes of apparent total body enzyme activity 
such as that observed in this study are potentially confounded 
by an age-dependent decline of specific organ functions. 
Previous studies demonstrated a deterioration in 11β-HSD2-
activity with deteriorating renal function.23,24 Here, this effect 
of renal function on 11β-HSD2 activity was experienced 
again. In addition, however, when only the group of subjects 
with a CrCl ≥60 ml/min/m2 was considered, a decline of the 
11β-HSD2 with age was observed, suggesting a strong influ-
ence of age on apparent 11β-HSD2 activity independent of 
renal function. The polynomial regression analysis used in our 
model identified a pronounced deterioration of apparent 11β-
HSD2 activity with diminished renal function, an observation 
with the potential to camouflage the age effect in patients with 
severely reduced renal function. Thus, on the basis of present 
findings and the known effect of renal function on 11β-HSD2 
activity, it is reasonable to conclude that both factors, age and 
the increasing prevalence of impaired renal function with age 
account for the observed reduction in 11β-HSD2 enzyme 
activity in elderly subjects with hypertension.23,24
Of interest, the multivariate linear regression model addition-
ally identified a reduced apparent 11β-HSD2 activity as assessed 
by the (THF + 5αTHF)/THE ratio in male patients. A simi-
lar gender effect on the (THF + 5αTHF)/THE ratio has been 
observed in a black population, where an increased 11β-HSD2 
activity was found in women when compared with men, sug-
gesting an augmented risk for male individuals to develop 
volume-dependent hypertension, a finding in line with the 
enhanced risk of male subjects to progress to hypertension.25
In this study exogenous and endogenous factors associated 
with renal- or age-related disease states or treatment known 
to affect 11β-HSD2 activity such as furosemide, nephrotic 
range proteinuria, liquorice consumption, or cholestasis were 
excluded.9,26–28 Renal function usually declines with age. 
Thus, a similar factor may account for the reduced 11β-HSD2 
activity as a function of the declining glomerular filtration rate 
or the increasing age. A plausible mechanism is a concomi-
tant quantitative reduction in enzyme availability as a conse-
quence of decreasing renal tubular cells with age and/or with 
declining glomerular filtration rate. Our findings, however, 
suggest in addition and independently to the reduced number 
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Table 3 | Multivariate linear regression analyses of the effect of age, gender, and creatinine clearance on cortisol production 
(N = 165)
Σ(F + E) Σ(THF + 5αTHF + THE)
Regression coefficient ± s.e. 95% CI P Regression coefficient ± s.e. 95% CI P
Age 0.103 ± 0.083 −0.062 to 0.269 0.22 3.28 ± 3.38 −3.42 to 9.98 0.33
Female gender 1.28 ± 2.38 −3.44 to 5.99 0.59 63.5 ± 96.3 −128 to 255 0.51
CrCl 0.024 ± 0.048 −0.071 to 0.120 0.61 2.41 ± 1.95 −1.45 to 6.28 0.22
5αTHF, 5α-tetrahydrocortisol; CI, confidence interval; CrCl, creatinine clearance; E, cortisone; F, cortisol; THE, tetrahydrocortisone; THF, tetrahydrocortisol.
Table 4 | Multivariate linear regression analyses of the 
effect of age, gender, and creatinine clearance on apparent 
11β-hydroxylase activity (N = 165)
THS/(THF + 5αTHF)
Regression 
coefficient ± s.e. 95% CI P
Age 0.0001 ± <0.001 0.000007 to 0.0002 0.04
Female gender 0.006 ± 0.002 0.003 to 0.009 <0.001
CrCl 0.00001 ± <0.001 −0.00006 to <0.00009 0.75
Boldface indicates significant differences.
5αTHF, 5α-tetrahydrocortisol; CI, confidence interval; CrCl, creatinine clearance; 
E, cortisone; F, cortisol; THE, tetrahydrocortisone; THF, tetrahydrocortisol.
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of functioning nephrons the activity of 11β-HSD2 to decline 
age-related. The reason of this specific age-related impaired 
activity of the enzyme is unknown. A potential candidate 
mechanism for a decreased gene expression is an increased 
DNA methylation in the elderly.12 This regulation might be 
relevant for the 11β-HSD2 enzyme, because we have recently 
shown that the degree of CpG-methylation in the promoter 
of the 11β-HSD2 gene determines activity and tissue specific 
expression of this enzyme.11
In summary, our results demonstrate a reduced 11β-HSD2-
activity in hypertensive patients with advancing age, an effect 
causing cortisol-mediated mineralocorticoid receptor activa-
tion. As a corollary, antihypertensive therapy should include 
inhibitors of the mineralocorticoid pathway in elderly subjects 
with hypertension, a reasoning supported by a recent clinical 
study by Chapman and co-workers.29 In that study comprising 
1,411 elderly subjects resistant to three antihypertensive drugs, 
the aldosterone receptor antagonist spironolactone induced an 
average drop in blood pressure of ≈22/10 mm Hg.29 In order 
to demonstrate unambiguously the role of the reduced 11β-
HSD2 for this tremendous therapeutic efficacy of spironol-
actone, prospective future studies will have to compare the 
effect of spironolactone in aged hypertensives with a reduced 
11β-HSD2 activity with that in subjects with a normal or high 
enzyme activity.
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